Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maveropepimut-S and Low-Dose Cyclophosphamide in Platinum-Resistant Ovarian Cancer
NCT05243524Phase 2Terminated
- Sponsor
- ImmunoVaccine Technologies Inc.
- Start
- Aug 2022
- Primary completion
- Jul 2023
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of maveropepimut-S in epithelial ovarian cancer (EOC), sponsored by ImmunoVaccine Technologies Inc. Primary endpoint: Objective Response Rate at 13 months. Started Aug 2022; status: terminated.
02
Drugs
maveropepimut-S
03
Conditions
epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT05243524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243524.